11.74
-0.76 (-6.08%)
新闻情绪
- MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
- MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing
AIStockmoo 评分
| 价值 30% | -0.5 |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 负债低。盈利能力弱。短期流动性充足。现金流为负。 参考 | |
| 资本回报低于资本成本。资本回报上升。 参考 | |
| 时机 30% | -3.0 |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 过去一年呈下降趋势。股价远低于52周高点。 参考 | |
| K线形态 参考 | NA |
| 您持有期的趋势 参考 | NA |
| 市场情绪 20% | 0.3 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻大多正面。 参考 | |
| 聪明钱 20% | 3.6 |
| 内部交易活动 参考 | NA |
| 机构在最新13F申报中净+19.19%的股份:103家增持,83家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化-23.4%,回补天数2.9天(FINRA)。 参考 | |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向不一,评分因此减弱。 | |
| 不计入评分 | |
| 股价低于其52周平均水平。5年来上涨。 参考 | |
| 短期动能上升。 参考 | |
| 股价处于支撑位与阻力位之间。 参考 | |
| 最终评分 | -0.24 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | MoonLake Immunotherapeutics | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| MLTX | - | - | - | 2.79 |
| TRML | 1 B | - | - | 4.76 |
| TECH | - | 0.44% | - | 5.28 |
| VKTX | - | - | - | 6.33 |
| VSTM | - | - | - | 76.50 |
| CRMD | - | - | - | 0.800 |
|
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 15.34% |
| 机构持股比例 | 96.70% |
该时间范围内无数据。
该时间范围内无数据。
机构
机构持股比例: 94.73%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 103 | 21,066,532 |
| 减持 | 83 | 10,045,773 |
| 新建仓 | 38 | 8,512,207 |
| 清仓 | 31 | 3,220,864 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 5,473,842 | 2.9 |
| 15 Oct 2026 | 7,833,997 | 4.1 |
| 30 Sep 2026 | 8,048,665 | 4.2 |
| 15 Sep 2026 | 8,947,906 | 6.1 |
| 31 Aug 2026 | 7,144,513 | 6.7 |
| 14 Aug 2026 | 6,819,147 | 4.2 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
MoonLake Immunotherapeutics (MLTX) Stock Could Be Above Fair Value On Book Value Concerns
MoonLake Immunotherapeutics has seen sharp swings over the past few years, and the latest share price level puts fresh focus on a simple question for you as an investor: Is the current valuation of MoonLake Immunotherapeutics stock meaningfully backed up by the strength of its balance sheet and its… |
| 11 Nov 2026 | Yahoo Finance |
MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing
MoonLake is developing Sonelokimab primarily for hidradenitis suppurativa (HS), a chronic inflammatory skin condition with limited effective treatments. |
| 10 Nov 2026 | Yahoo Finance |
Is MoonLake Immunotherapeutics (MLTX) Cheap On Earnings Losses And Sonelokimab Milestones?
MoonLake Immunotherapeutics (MLTX) just posted third quarter 2026 results, reporting a net loss of US$79.55 million and a diluted loss per share of US$0.93. The company also reaffirmed its focus on sonelokimab regulatory milestones. The latest earnings update landed after a sharp pullback, with… |
| 09 Nov 2026 | Yahoo Finance |
MoonLake Immunotherapeutics Stock In Focus After Quarterly Loss Update
MoonLake Immunotherapeutics reported third quarter 2026 results with a net loss of US$79.55 million and basic and diluted loss per share of US$0.93, and a nine month 2026 net loss of US$211.06 million with basic and diluted loss per share of US$2.74. The narrower quarterly loss per share compared… |
| 04 Nov 2026 | Yahoo Finance |
MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, marking an important step towards potential U.S. approval and commercializationPositive Week 16 results from… |
| 25 Oct 2026 | Yahoo Finance |
MoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View Holds
Recent Performance Snapshot MoonLake Immunotherapeutics (MLTX) has drawn fresh attention after recent trading saw the share price close at $11.85. Performance has been mixed across timeframes and marked by sharp moves over the past 3 months. That recent jump in MoonLake Immunotherapeutics, with a… |
| 24 Oct 2026 | Yahoo Finance |
MoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet Questions
MoonLake Immunotherapeutics has seen sharp swings in its share price in recent years, which puts fresh focus on what investors are really paying for on the balance sheet. With the stock last closing at US$11.85, the live question is how that market tag lines up with the company’s book value. The… |
| 22 Oct 2026 | Yahoo Finance |
AbbVie Slips Behind Rivals as Lutikizumab Hits 31.4% Response in HS Trial
Key TakeawaysAbbVie’s lutikizumab met its Phase 3 goal in hidradenitis suppurativa, with 31. 4% of patients reaching HiSCR75 at Week 16 versus 23… |
| 22 Oct 2026 | Yahoo Finance |
MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”
Key TakeawaysMoonLake shares jumped 18% today after AbbVie reported Phase 3 results for a rival hidradenitis suppurativa drug. AbbVie’s lutikizumab beat placebo by 8 percentage points on its main goal, a result RBC Capital called underwhelming. |
| 16 Oct 2026 | Yahoo Finance |
MoonLake Immunotherapeutics Makes Case for Sonelokimab Approval, RBC Says
MoonLake Immunotherapeutics (MLTX) made a "reasonably solid" case for the approvability of sonelokim… |
| 05 Oct 2026 | Yahoo Finance |
MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says
MoonLake Immunotherapeutics (MLTX) could receive US Food and Drug Administration approval for sonelo… |
| 21 Sep 2026 | Yahoo Finance |
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics)… |
| 11 Sep 2026 | Yahoo Finance |
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high. |
| 显示更多 | ||
投资组合